This study is an open-label, long-term study for those patients who participated in the prior proof-of-concept protocol, in which the preliminary efficacy for B…

United States10 participantsStarted 2014-03-11

Treatment: BYM338 (Bimagrumab)

CompletedPhase 2/3

NCT01925209

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physica…

United States251 participantsStarted 2013-09-26

Treatment: BYM338/bimagrumab, Placebo

Sporadic Inclusion Body Myositis (sIBM)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

All recent trials (4 shown)

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

All recent trials (4 shown)

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

Pharmacoepidemiologic General Research Extension: PGRx-sIBM Study